NEW YORK (GenomeWeb News) – Nanotechnology firm NanoInk today said that it has launched a new division called NanoBioDiscovery that will focus on supplying technologies for biomarker research and drug discovery.
 
The Skokie, Ill.-based firm said that the new division will use its Dip Pen Nanolithography nanofabrication techniques and detection systems to produce assays for protein discovery and identification. It believes its technology can provide researchers with enhanced reaction kinetics and assay cost savings.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.